ICICI Securities Limited
BSE NSE

Molbio Diagnostics Limited IPO

Mainboard Closed
  • IPO Open Date
  • 10th Aug 2026
  • IPO Close Date
  • 12th Aug 2026
  • Allotment date
  • 13th Aug 2026
  • Listing date
  • 17th Aug 2026
  • Issue Size
  • ₹ 940 Cr.
  • Issue Price Band
  • ₹ 768 to 807
  • Lot Size
  • 18 Share
  • Minimum Investment
  • ₹ 14526

Disclaimer: IPO details, GMP, subscription figures, and other related information are for informational purposes only and may not always be accurate or up to date. Please verify the latest details from official sources before investing.

About Molbio Diagnostics Limited

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialisation of rapid diagnostic solutions for infectious and non-communicable diseases.

The company has developed its proprietary ‘Truenat’ platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.

Product Portfolio

Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV.

Through its subsidiaries and strategic collaborations, the company also provides radiology, digital pathology, and breast health screening solutions, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.

Global Presence & Operations

The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organisations.

Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.

Workforce

As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.

Competitive Strengths

  • Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology
  • Strong R&D capabilities supported by an extensive global patent portfolio
  • Scalable business model with recurring revenues from diagnostic test kits
  • Global presence across 90+ countries with strong government and institutional customer base
  • Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio
  • Experienced management team with deep expertise in molecular diagnostics and healthcare innovation
Read More

IPO Subscription Details

Category Shares Offered Shares Applied Subscription Times (x)
QIB (Ex Anchor) 23,25,145 (28.50%) 43,33,82,148 186.39
NII 17,43,860 (21.37%) 8,68,40,604 49.80
bNII (> ₹10L) 11,62,574 (14.25%) 5,90,76,594 50.82
sNII (< ₹10L) 5,81,286 (7.12%) 2,77,64,010 47.76
Retail 40,69,005 (49.87%) 5,27,19,318 12.96
Employee 20,519 (0.25%) 2,72,466 13.28
Total 81,58,529 (100.00%) 57,32,14,536 70.26
Updated on 2026-08-14 21:57:31

Grey Market Premium (GMP)

GMP Date IPO Price GMP Estimated Listing Price Estimated Profit* Last Updated
12-08-2026 ₹807 ₹138 ₹945 ( 17.10% ) ₹2,484.00 12-Aug-2026 10:21 AM
11-08-2026 ₹807 ₹127 ₹934 ( 15.74% ) ₹2,286.00 11-Aug-2026 09:56 AM
10-08-2026 ₹807 ₹132 ₹939 ( 16.36% ) ₹2,376.00 10-Aug-2026 10:23 AM
08-08-2026 ₹807 ₹130 ₹937 ( 16.11% ) ₹2,340.00 08-Aug-2026 10:14 AM
07-08-2026 ₹807 ₹205 ₹1012 ( 25.40% ) ₹3,690.00 07-Aug-2026 10:34 AM
06-08-2026 ₹807 ₹200 ₹1007 ( 24.78% ) ₹3,600.00 06-Aug-2026 12:41 PM
Disclaimer: Grey Market Premium (GMP) is an unofficial market indicator provided for informational purposes only. It may change at any time and should not be considered investment advice or a guarantee of listing gains. Please evaluate company fundamentals, financials, valuation, and subscription data, and consult a SEBI-registered financial advisor before making any investment decision.

Financials of Molbio Diagnostics Limited

A quick overview of the key financial performance of Molbio Diagnostics Limited.

Total Assets (₹ Cr)

Revenue (₹ Cr)

Profit after Tax (₹ Cr)

*All values are in Rs. Cr

Company Financials

Revenue increased by 42%, Profit after Tax (PAT) increased by 18%, Total Assets increased by 47% between FY2025 and FY2026.

Period Ended FY2024 FY2025 FY2026
Revenue 840.66 1,027.94 1,455.17
Assets 1,221.06 1,461.56 2,148.42
Total Income 840.66 1,027.94 1,455.17
Profit After Tax 83.54 138.58 164.14
EBITDA 185.09 256.64 328.24
Net Worth 807.94 952.95 1,144.68
Reserves & Surplus 821.13 966.14 1,158.06
Total Borrowings 174.58 123.16 412.64
Amount in ₹ Crore

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 18 ₹ 14,526
Retail (Max) 13 234 ₹ 1,88,838
S-HNI (Min) 14 252 ₹ 2,03,364
S-HNI (Max) 68 1,224 ₹ 9,87,768
B-HNI (Min) 69 1,242 ₹ 10,02,294

Key Performance Indicators (KPI)

KPI Latest
ROE (%) 15.59
ROCE (%) 17.55
RoNW (%) 14.55
PAT Margin (%) 11.28
EBITDA Margin (%) 22.56
Pre IPO
Post IPO
EPS (₹)
14.77
-
P/E (x)
-
-
Promoter Holding (%)
46.65
-
Disclaimer: KPI values are based on information disclosed in the IPO prospectus and are provided for informational purposes only.

IPO Lead Manager(s)

Lead Manager Details

  • Kotak Mahindra Capital Company Limited

Lead Manager Details

  • IIFL Capital Services Limited (formerly known as IIFL Securities Limited)

Lead Manager Details

  • Jefferies India Private Limited

Lead Manager Details

  • Motilal Oswal Investment Advisors Limited

IPO Registrar

  • Registrar Name
  • KFin Technologies Limited
  • Phone
  • +91 40 6716 2222 / 1800 3094001
  • Contact Person
  • M. Murali Krishna
  • SEBI Registration Number
  • INR000000221
  • Address
  • Selenium, Tower B, Plot No. 31 and 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad 500 032, Telangana, India

Company Contact Details

  • Company Name
  • Molbio Diagnostics Limited
  • Phone
  • +91 832 6724888
  • Contact Person
  • Darshan Raghunath Karekar, Company Secretary and Compliance Officer
  • Corporate Identity Number
  • U33125GA2000PLC002909
  • Address
  • Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa 403722, Goa, India

Molbio Diagnostics Limited FAQs

The Molbio Diagnostics Limited IPO is a MAIN IPO with a total issue size of ₹ 940 crores. The IPO price band is fixed at ₹768 to ₹ 807 per share, and the minimum lot size is 18 Shares. The Molbio Diagnostics Limited IPO will open on 10th Aug 2026, and will close on 12th Aug 2026. KFin Technologies Limited has been appointed as the registrar for the issue. The equity shares are proposed to be listed on BSE,NSE.

The Molbio Diagnostics Limited IPO opens on 10th Aug 2026 and closes on 12th Aug 2026.

The Molbio Diagnostics Limited IPO lot size is 18 Share, and the minimum amount required for application is ₹ 14526.

You can apply for the Molbio Diagnostics Limited IPO through your bank account using the ASBA facility or via your online trading and Demat account. To apply online, log in to your broker’s platform, select Molbio Diagnostics Limited IPO, enter the number of lots, choose your price within the price band, and submit the application. After submitting, approve the UPI mandate to block the required amount in your bank account. Once the IPO allotment is finalised, shares will be credited to your Demat account if allotted. If not allotted, the blocked amount will be released automatically.

The Molbio Diagnostics Limited IPO listing date is 17th Aug 2026.
Chat
Investkraft Assistant Beta Version
Powered by AI
👋 Hi! Before we start, may I know your name?
Scroll Top ↑
WhatsApp
Subcribe - Investkraft Newsletter

Subscribe to our newsletter